{"name":"Coloplast","slug":"coloplast","ticker":"COLO-B","exchange":"CPH","domain":"coloplast.com","description":"Coloplast A/S is a Danish multinational company that develops, manufactures and markets medical devices and services related to ostomy, urology, continence, and wound care.","hq":"Humlebæk, Denmark","founded":1957,"employees":"16983","ceo":"Kristian Villumsen","sector":"Ostomy / Continence / Wound Care","stockPrice":434.9,"stockChange":9.7,"stockChangePercent":2.28,"marketCap":"$98.0B","metrics":{"revenue":27890999296,"revenueGrowth":0.2,"grossMargin":67.9,"rdSpend":0,"netIncome":3988999936,"cash":1124999936,"dividendYield":5.19,"peRatio":24.6,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Silhouette patent cliff ($100M at risk)","drug":"Silhouette","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Milo patent cliff ($50M at risk)","drug":"Milo","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-01","type":"earnings","headline":"Coloplast Reports Strong Q4 2023 Earnings","summary":"Coloplast reported strong Q4 2023 earnings, driven by growth in its ostomy and continence care businesses.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"deal","headline":"Coloplast Acquires Urology Product Line from Medtronic","summary":"Coloplast acquired a urology product line from Medtronic, expanding its presence in the urology market.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxON0tKQmRxaWVnVkhWX0VZZkRDRlNhd1BmQl95NmhheVl3TDJmR3NWbldtaGhCWFNZUExEOWNnYkI4ODJyR3dCd0J3M0x6UUdSOEU4SU02RjJvbnAwN2dQQWFDb1VKUEJoWkJ6YmExYWJHZWo3VDlUUF9ZN0p4NUJva1dDcDlRYzcwZFIwM3JkQ0RaeDFuZU1JWGIyU19sLXJJTm5MdnBELWVxcnA2d1Q4MURB?oc=5","date":"2026-04-07","type":"pipeline","source":"marketscreener.com","summary":"Coloplast drops 3 percent following Goldman Sachs downgrade - marketscreener.com","headline":"Coloplast drops 3 percent following Goldman Sachs downgrade","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-18","type":"pipeline","source":"simplywall.st","summary":"A Look At Coloplast’s (CPSE:COLO B) Valuation As Gavin Wood Is Appointed Incoming CEO - simplywall.st","headline":"A Look At Coloplast’s (CPSE:COLO B) Valuation As Gavin Wood Is Appointed Incoming CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNbnBKRS1nSXdUVGptXzctYi1vUVMwWnM1RHNEX3BySFRqU1dVUUpkLTBldGpWS3BFVUtqOHMwNFllQmx6Q1ZTUU1kazhTVERUNnFQX0k1TlR0TV9iMlZhcnhFU0xqOWxnZmxFMEVRMFltRkJWRFJDZWdWRUNMNmtWWGdLYw?oc=5","date":"2026-03-13","type":"pipeline","source":"Yahoo Finance","summary":"How The Coloplast (CPSE:COLO B) Narrative Is Shifting As Analysts Recalibrate Valuation Assumptions - Yahoo Finance","headline":"How The Coloplast (CPSE:COLO B) Narrative Is Shifting As Analysts Recalibrate Valuation Assumptions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPMmpKaTZYZFZ3cGE1UTc5SDRhOUhXWUotcW45NDJrb2xtemN4UDYxQjR4b3hqMkd6dGtUOTF1aXhUZkNVR3FSTnNoLUJnN1czcmxmclpRalVVUDJTcDdxeTRaSTJWUFF0OVFOamt4M0ZGM1RnR2ZyZmRpdmp3VWtrNF8wLWRFM2x3QUJ6NFNVZkN0ZHhzMElOUjdWX2dneTRCMi1QU2R4S2kyVzFwWFE?oc=5","date":"2026-01-02","type":"pipeline","source":"Seeking Alpha","summary":"Coloplast – Premium Valuation And Pedestrian Results Have Been A Bad Mix (OTCMKTS:CLPBY) - Seeking Alpha","headline":"Coloplast – Premium Valuation And Pedestrian Results Have Been A Bad Mix (OTCMKTS:CLPBY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOZWZtUFo0NVNGWExOMUNLRU9GN3hBSTFXQTZTRGYzMmFMRUd2Z2ZESHBoNEZ5VVlFU2wxZWRQM3BfbnctUjJ6bmxMaHNYdkEwSEZoZDVXY1JQX1BtbTZBMG9hVkhwdVNBX0l5dkhteGFnbVFKMHNEekVpb2xpVnZmbDJsV29HMmxFRkFCaHl3TElsVjA?oc=5","date":"2025-12-01","type":"pipeline","source":"Morningstar Canada","summary":"Where Nordic Investors Should Look for Value in 2026 - Morningstar Canada","headline":"Where Nordic Investors Should Look for Value in 2026","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-30","type":"deal","source":"simplywall.st","summary":"Do These 3 Checks Before Buying Coloplast A/S (CPH:COLO B) For Its Upcoming Dividend - simplywall.st","headline":"Do These 3 Checks Before Buying Coloplast A/S (CPH:COLO B) For Its Upcoming Dividend","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-01","type":"pipeline","source":"simplywall.st","summary":"Coloplast (CPH:COLO B) investors are sitting on a loss of 36% if they invested five years ago - simplywall.st","headline":"Coloplast (CPH:COLO B) investors are sitting on a loss of 36% if they invested five years ago","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFBVdVcwbmNZMjFCaW9rVGFWTlQyb1RUejBqRVE5dUN4UVh4RHpyWFJMY1VfMHRkR3JTU2ljMzMtOEFyUEF3RlN6b1hyOTItbDhCcWl6NGdKQlZBMGlOMTFMcHpMZXNZV0JXQVJzY2tISFFYRmY3YmMyM3Y4dw?oc=5","date":"2025-06-20","type":"deal","source":"Morningstar Canada","summary":"The Best Healthcare Stocks to Buy | Morningstar Europe - Morningstar Canada","headline":"The Best Healthcare Stocks to Buy | Morningstar Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNWXpiSU9vUzNfX093ZFBXNTd2VWY2bkZJNWNKTU1vX1BRZ1FadmtlWWpRelljR2RoanRPWmRNRjJOZl9GVWZiaVVKYkJzSFFhTHg0NGxidXFDMVFxZi1oaXpRdGYxUFFtYjFJUkxxQWJxZV82UmFiOFJuZnVMVUFfOXFIMWh5eHM4X3pJalRqRS01ZnZ4WlRR?oc=5","date":"2025-01-22","type":"pipeline","source":"Morningstar Canada","summary":"7 Nordic Stocks Every Global Investor Should Own - Morningstar Canada","headline":"7 Nordic Stocks Every Global Investor Should Own","sentiment":"neutral"}],"patents":[{"drugName":"Silhouette","drugSlug":"silhouette","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000},{"drugName":"Milo","drugSlug":"milo","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":50000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["ConvaTec","B. Braun","3M"],"therapeuticFocus":["Ostomy and Continence Care","Wound Care","Urology"],"financials":null,"yahoo":{"currentPrice":434.9,"previousClose":425.2,"fiftyTwoWeekHigh":748,"fiftyTwoWeekLow":418.3,"fiftyTwoWeekRange":"418.3 - 748.0","fiftyDayAverage":474.78,"twoHundredDayAverage":558.95,"beta":0.58,"enterpriseValue":119711924224,"forwardPE":16,"priceToBook":7.09,"priceToSales":3.51,"enterpriseToRevenue":4.29,"enterpriseToEbitda":13.95,"pegRatio":1.27,"ebitda":8584000000,"ebitdaMargin":30.8,"freeCashflow":3469625088,"operatingCashflow":6871000064,"totalDebt":25095999488,"debtToEquity":181.8,"currentRatio":1.3,"returnOnAssets":9.9,"returnOnEquity":27.3,"analystRating":"2.8 - Hold","recommendationKey":"hold","numberOfAnalysts":19,"targetMeanPrice":560.63,"targetHighPrice":760,"targetLowPrice":400,"dividendRate":23,"payoutRatio":1.3,"fiveYearAvgDividendYield":2.61,"exDividendDate":1764892800,"insiderHeldPercent":29.8,"institutionHeldPercent":29.5,"sharesOutstanding":207366796,"floatShares":143383964,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":17.71,"epsForward":27.18,"revenuePerShare":123.74,"bookValue":61.31,"officers":[{"age":66,"name":"Mr. Lars Soren Rasmussen Ph.D.","title":"Interim CEO & President"},{"age":53,"name":"Mr. Anders  Lonning-Skovgaard","title":"Executive VP & CFO"},{"age":58,"name":"Mr. Allan  Rasmussen","title":"Executive Vice President of Global Operations"},{"age":56,"name":"Mr. Nicolai Buhl Andersen","title":"Executive Vice President of Chronic Care"},{"age":55,"name":"Mr. Thomas  Barfod","title":"Senior Controller & Employees Representative Director"},{"age":null,"name":"Aleksandra  Dimovska","title":"Vice President of Investor Relations"},{"age":null,"name":"Mr. Dennis  Kaysen","title":"Vice President of Corporate Communications"},{"age":null,"name":"Mads  Mikkelsen","title":"VP of People & Culture - Chronic Care Commercial and Interim Head of Global People & Culture"}],"industry":"Medical Instruments & Supplies","irWebsite":"http://www.coloplast.com/about/investorrelations/shareinformation/","website":"https://www.coloplast.com","phone":"45 49 11 11 11"}}